-+ 0.00%
-+ 0.00%
-+ 0.00%
Sobi's Tryngolza Wins EU Approval for Severe Hypertriglyceridemia
Share
Listen to the news
Sobi's Tryngolza Wins EU Approval for Severe Hypertriglyceridemia
  • Sobi’s Tryngolza (olezarsen) won European Commission approval to treat adults with severe hypertriglyceridemia, expanding its existing authorization.
  • The approval covers fasting triglycerides of at least 880 mg/dL, as an adjunct to diet alongside other lipid-lowering therapies.
  • Trials showed triglyceride reductions up to 73% at six months versus placebo; acute pancreatitis episodes fell 83% over 12 months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Swedish Orphan Biovitrum AB published the original content used to generate this news brief via Cision (Ref. ID: 202611170300BITN____UKPR__SV_20261116-BIT-0019-0) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending